Literature DB >> 3932270

Late cardiac, thyroid, and pulmonary sequelae of mantle radiotherapy for Hodgkin's disease.

G W Morgan, A P Freeman, R G McLean, B H Jarvie, R W Giles.   

Abstract

Cardiac, thyroid and pulmonary function were evaluated in 25 patients aged 35 years or under, treated for Hodgkin's disease by mantle radiotherapy 5-16 years previously. No patient had symptoms of heart disease. Although thallium myocardial perfusion scintigraphy was normal in all patients, abnormalities of myocardial function were detected in 6 (24%) patients using gated equilibrium rest and exercise radionuclide ventriculography. Resting left ventricular ejection fraction (LVEF) was abnormal in 1 patient, and in 3 patients there was an abnormal LVEF response to exercise. All 6 patients had right ventricular dilatation. Apical hypokinesia was present in 4 of these patients. A small asymptomatic pericardial effusion was detected by M-Mode echocardiography in only 2 (8%) patients. Twenty-three (92%) patients had evidence of abnormal thyroid function. Two (8%) patients had become clinically hypothyroid. Serum TSH was elevated in 13 (52%) patients and TRH stimulation test was abnormal in a further 10 (40%) patients in whom TSH was normal. Pulmonary function studies showed a moderate decrease in diffusing capacity (72% of predicted) and a minor reduction in lung volume. Although a high incidence of cardiac, thyroid and pulmonary abnormalities was detected, only the 2 patients who had become hypothyroid were symptomatic. Modification of the irradiation technique may reduce the incidence of cardiac abnormalities, but is unlikely to alter significantly the thyroid or pulmonary sequelae.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3932270     DOI: 10.1016/0360-3016(85)90273-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  Myocardial perfusion damage after mediastinal irradiation for Hodgkin's disease: a thallium-201 single photon emission tomography study.

Authors:  C Maunoury; J Y Pierga; H Valette; G Tchernia; J M Cosset; A Desgrez
Journal:  Eur J Nucl Med       Date:  1992

2.  Retrospective estimation of heart and lung doses in pediatric patients treated with spinal irradiation.

Authors:  Daniel Gasic; Per Munck Af Rosenschöld; Ivan R Vogelius; Maja V Maraldo; Marianne C Aznar; Karsten Nysom; Thomas Björk-Eriksson; Søren M Bentzen; Nils Patrik Brodin
Journal:  Radiother Oncol       Date:  2018-05-30       Impact factor: 6.280

Review 3.  Complete AV block following mediastinal radiation therapy: electrocardiographic and pathologic correlation and review of the world literature.

Authors:  B M Kaplan; A J Miller; S Bharati; M Lev; I Martin Grais
Journal:  J Interv Card Electrophysiol       Date:  1997-11       Impact factor: 1.900

4.  Iodine-123 metaiodobenzylguanidine in the assessment of late cardiac effects from cancer therapy.

Authors:  R A Valdés Olmos; W W ten Bokkel Huinink; L G Dewit; C A Hoefnagel; I H Liem; H van Tinteren
Journal:  Eur J Nucl Med       Date:  1996-04

5.  Late cardiac effects after treatment for childhood Hodgkin's disease with chemotherapy and low-dose radiotherapy.

Authors:  I Ilhan; F Sarialioglu; N Ozbarlas; M Büyükpamukçu; C Akyüz; T Kutluk
Journal:  Postgrad Med J       Date:  1995-03       Impact factor: 2.401

6.  Inhibition of glioma cell line A-172 MMP activity and cell invasion in vitro by a nutrient mixture.

Authors:  M Waheed Roomi; Vadim Ivanov; Tatiana Kalinovsky; Aleksandra Niedzwiecki; Matthias Rath
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

7.  Late cardiopulmonary toxicity after treatment for Hodgkin's disease.

Authors:  C Allavena; T Conroy; P Aletti; P Bey; P Lederlin
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

8.  High incidence of late effects found in Hodgkin's lymphoma survivors, following recall for breast cancer screening.

Authors:  D M Greenfield; J Wright; J E Brown; B W Hancock; H A Davies; L O'Toole; C Eiser; R E Coleman; R J Ross
Journal:  Br J Cancer       Date:  2006-02-27       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.